Call us now : +91 80 28528900, 01, 02


DeQuantoTM Rituximab (Mabthera ) PK ELISA KIT (Catalog # PK1004)

CATALOG # : PK1004

Pack Size : 1 x 96 wells

QTY : 1

PRICE : Enquire

  • Product Specifications

    • Sensitivity: 6.25 ng/ml
    • Very cost effective
    • Assay Duration:3.15-3.30 Hrs
    • Assay range: 6.25-200 ng/ml
    • Assay Matrix: Tested and validated for Human serum or plasma
    • Specificity: Specifically to rituximab drug
    • Interference: No interference observed for Infliximab (Remicade) and Etanercept (Enbrel) in the assay range
    • Note: "Mabthera®" is a registered trademark of Roche Inc.

    The kit is based on very robust ELISA technique and with very high sensitivity.

  • Product Summary


    Rituximab (Mabthera) is a genetically engineered chimeric murine/human monoclonal antibody specific to CD20. CD20 is an approximately 35 KDa transmembrane phosphoprotein involved in the activation, proliferation, and differentiation of B-lymphocytes. It is absent in terminally differentiated plasma cells.Mabthera® is a registered trademark of Roche, Inc.

    The Fab domain of rituximab binds to the CD20 antigen on B-lymphocytes and the Fc domain recruits immune effector functions to induce apoptosis in B cells and is used in the treatment of leukemia s and lymphomas, some autoimmune disorders, and organ transplant.

    EMA Bio-analytical Method Validation Guidelines and industry-recommended practices for ligand-binding assays were used for validation of this kit. The Rituximab ELISA kit is designed to quantify/measure the Rituximab with high specificity and sensitivity in biological matrices.

    Assay Principle

    DeQuantoTM Rituximab (Mabthera) PK ELISA kit is a sandwich immunoassay. The Rituximab present in the sample binds to pre coated Anti-Rituximab Antibody on polystyrene microtiter plate. Non bound or the excess substances are removed by washing. Horseradish Peroxidase (HRP) labeled antibody is added to the wells.

    The plate is washed to remove any unbound antibody-enzyme reagent and substrate solution is added to the wells. A color product is formed in proportion to the amount of Rituximab present in the sample or standards. The color development is stopped by addition of a stop solution. The absorbance is measured at 450 nm in a microtiter plate reader. The concentration of Rituximab in a sample can be interpolated from the standard curve.